Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands  | 
3 Months Ended | ||
|---|---|---|---|
Sep. 30, 2016  | 
Sep. 30, 2015  | 
Jun. 30, 2016  | 
|
| Advanced Cell Diagnostics (ACD) [Member] | Available-for-sale Securities [Member] | |||
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities | $ 5,700 | ||
| Advanced Cell Diagnostics (ACD) [Member] | |||
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory | 12,800 | ||
| Certificates of Deposit [Member] | CHINA | |||
| Payments to Acquire Available-for-sale Securities | 5,200 | ||
| ChemoCentryx, Inc (CCXI) [Member] | |||
| Available-for-sale Equity Securities, Gross Unrealized Gain | 9,900 | ||
| Available-for-sale Equity Securities, Amortized Cost Basis | 29,500 | $ 29,500 | |
| Available-for-sale Securities | 52,400 | 31,600 | |
| Payments to Acquire Available-for-sale Securities | 6,836 | ||
| Inventory Valuation Reserves | $ 24,000 | $ 24,000 | |
| X | ||||||||||
- Definition This item represents the cost of equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments for other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any. No definition available. 
  | 
| X | ||||||||||
- Definition Amount of unrealized gain before deducting unrealized loss on investments in equity securities classified as available-for-sale securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef 
  | 
| X | ||||||||||
- Definition Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading. Reference 1: http://www.xbrl.org/2003/role/presentationRef 
  | 
| X | ||||||||||
- Definition Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef 
  | 
| X | ||||||||||
- Definition The amount of inventory recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef 
  | 
| X | ||||||||||
- Definition Amount of valuation reserve for inventory. Reference 1: http://www.xbrl.org/2003/role/presentationRef 
  | 
| X | ||||||||||
- Definition The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef 
  | 
| X | ||||||||||
- Details 
  | 
| X | ||||||||||
- Details 
  | 
| X | ||||||||||
- Details 
  | 
| X | ||||||||||
- Details 
  | 
| X | ||||||||||
- Details 
  |